vs
Harmony Biosciences Holdings, Inc.（HRMY）与STURM RUGER & CO INC（RGR）财务数据对比。点击上方公司名可切换其他公司
Harmony Biosciences Holdings, Inc.的季度营收约是STURM RUGER & CO INC的1.6倍（$243.8M vs $151.1M），Harmony Biosciences Holdings, Inc.同比增速更快（21.1% vs 3.6%），Harmony Biosciences Holdings, Inc.自由现金流更多（$126.0M vs $12.3M），过去两年Harmony Biosciences Holdings, Inc.的营收复合增速更高（25.6% vs 5.1%）
哈莫尼生物科学控股公司是一家处于商业化阶段的生物制药企业，专注于罕见神经及中枢神经系统疾病创新疗法的研发与商业化，核心产品针对发作性睡病等睡眠相关中枢神经系统病症，主要市场为美国。
鲁格公司（Ruger）是总部位于美国康涅狄格州绍斯波特的枪械制造企业，除总部外，还在新罕布什尔州纽波特、北卡罗来纳州梅约丹以及亚利桑那州普雷斯科特设有生产工厂。公司由亚历山大·麦考密克·斯特姆与威廉·B·鲁格于1949年共同创立，自1969年起公开上市交易。
HRMY vs RGR — 直观对比
营收规模更大
HRMY
是对方的1.6倍
$151.1M
营收增速更快
HRMY
高出17.5%
3.6%
自由现金流更多
HRMY
多$113.7M
$12.3M
两年增速更快
HRMY
近两年复合增速
5.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $243.8M | $151.1M |
| 净利润 | $22.5M | — |
| 毛利率 | 71.9% | 17.8% |
| 营业利润率 | 15.8% | 2.3% |
| 净利率 | 9.2% | — |
| 营收同比 | 21.1% | 3.6% |
| 净利润同比 | -54.6% | — |
| 每股收益（稀释后） | $0.38 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HRMYRGR
| Q4 25 | $243.8M | $151.1M | ||
| Q3 25 | $239.5M | $126.8M | ||
| Q2 25 | $200.5M | $132.5M | ||
| Q1 25 | $184.7M | $135.7M | ||
| Q4 24 | $201.3M | $145.8M | ||
| Q3 24 | $186.0M | $122.3M | ||
| Q2 24 | $172.8M | $130.8M | ||
| Q1 24 | $154.6M | $136.8M |
净利润HRMYRGR
| Q4 25 | $22.5M | — | ||
| Q3 25 | $50.9M | $1.6M | ||
| Q2 25 | $39.8M | $-17.2M | ||
| Q1 25 | $45.6M | $7.8M | ||
| Q4 24 | $49.5M | — | ||
| Q3 24 | $46.1M | $4.7M | ||
| Q2 24 | $11.6M | $8.3M | ||
| Q1 24 | $38.3M | $7.1M |
毛利率HRMYRGR
| Q4 25 | 71.9% | 17.8% | ||
| Q3 25 | 75.1% | 15.1% | ||
| Q2 25 | 81.0% | 3.9% | ||
| Q1 25 | 82.7% | 22.0% | ||
| Q4 24 | 73.0% | 22.8% | ||
| Q3 24 | 77.0% | 18.5% | ||
| Q2 24 | 81.4% | 22.3% | ||
| Q1 24 | 82.2% | 21.5% |
营业利润率HRMYRGR
| Q4 25 | 15.8% | 2.3% | ||
| Q3 25 | 27.3% | -2.7% | ||
| Q2 25 | 24.0% | -15.6% | ||
| Q1 25 | 30.4% | 6.2% | ||
| Q4 24 | 27.7% | 7.8% | ||
| Q3 24 | 33.2% | 3.1% | ||
| Q2 24 | 12.4% | 6.9% | ||
| Q1 24 | 33.7% | 5.5% |
净利率HRMYRGR
| Q4 25 | 9.2% | — | ||
| Q3 25 | 21.2% | 1.2% | ||
| Q2 25 | 19.8% | -13.0% | ||
| Q1 25 | 24.7% | 5.7% | ||
| Q4 24 | 24.6% | — | ||
| Q3 24 | 24.8% | 3.9% | ||
| Q2 24 | 6.7% | 6.3% | ||
| Q1 24 | 24.8% | 5.2% |
每股收益（稀释后）HRMYRGR
| Q4 25 | $0.38 | $0.22 | ||
| Q3 25 | $0.87 | $0.10 | ||
| Q2 25 | $0.68 | $-1.05 | ||
| Q1 25 | $0.78 | $0.46 | ||
| Q4 24 | $0.85 | $0.62 | ||
| Q3 24 | $0.79 | $0.28 | ||
| Q2 24 | $0.20 | $0.47 | ||
| Q1 24 | $0.67 | $0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $775.3M | $92.5M |
| 总债务越低越好 | $163.7M | — |
| 股东权益账面价值 | $870.2M | $283.8M |
| 总资产 | $1.3B | $342.0M |
| 负债/权益比越低杠杆越低 | 0.19× | — |
8季度趋势，按日历期对齐
现金及短期投资HRMYRGR
| Q4 25 | $775.3M | $92.5M | ||
| Q3 25 | $672.6M | $80.8M | ||
| Q2 25 | $565.3M | $101.4M | ||
| Q1 25 | $507.0M | $108.3M | ||
| Q4 24 | $467.2M | $105.5M | ||
| Q3 24 | $410.5M | $96.0M | ||
| Q2 24 | $346.9M | $105.6M | ||
| Q1 24 | $372.4M | $115.3M |
总债务HRMYRGR
| Q4 25 | $163.7M | — | ||
| Q3 25 | $168.5M | — | ||
| Q2 25 | $172.1M | — | ||
| Q1 25 | $175.7M | — | ||
| Q4 24 | $179.3M | — | ||
| Q3 24 | $182.8M | — | ||
| Q2 24 | $186.4M | — | ||
| Q1 24 | $190.0M | — |
股东权益HRMYRGR
| Q4 25 | $870.2M | $283.8M | ||
| Q3 25 | $835.1M | $279.6M | ||
| Q2 25 | $773.1M | $289.3M | ||
| Q1 25 | $720.5M | $321.5M | ||
| Q4 24 | $659.2M | $319.6M | ||
| Q3 24 | $596.8M | $314.9M | ||
| Q2 24 | $538.6M | $321.5M | ||
| Q1 24 | $515.4M | $332.0M |
总资产HRMYRGR
| Q4 25 | $1.3B | $342.0M | ||
| Q3 25 | $1.2B | $342.3M | ||
| Q2 25 | $1.1B | $349.5M | ||
| Q1 25 | $1.1B | $379.0M | ||
| Q4 24 | $999.2M | $384.0M | ||
| Q3 24 | $928.1M | $373.5M | ||
| Q2 24 | $858.4M | $376.7M | ||
| Q1 24 | $847.0M | $385.0M |
负债/权益比HRMYRGR
| Q4 25 | 0.19× | — | ||
| Q3 25 | 0.20× | — | ||
| Q2 25 | 0.22× | — | ||
| Q1 25 | 0.24× | — | ||
| Q4 24 | 0.27× | — | ||
| Q3 24 | 0.31× | — | ||
| Q2 24 | 0.35× | — | ||
| Q1 24 | 0.37× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $126.2M | $15.5M |
| 自由现金流经营现金流 - 资本支出 | $126.0M | $12.3M |
| 自由现金流率自由现金流/营收 | 51.7% | 8.2% |
| 资本支出强度资本支出/营收 | 0.0% | 2.1% |
| 现金转化率经营现金流/净利润 | 5.61× | — |
| 过去12个月自由现金流最近4个季度 | $347.9M | $38.5M |
8季度趋势，按日历期对齐
经营现金流HRMYRGR
| Q4 25 | $126.2M | $15.5M | ||
| Q3 25 | $108.7M | $12.9M | ||
| Q2 25 | $79.3M | $14.7M | ||
| Q1 25 | $34.0M | $11.1M | ||
| Q4 24 | $75.6M | $20.0M | ||
| Q3 24 | $70.5M | $9.4M | ||
| Q2 24 | $42.6M | $18.7M | ||
| Q1 24 | $31.1M | $7.3M |
自由现金流HRMYRGR
| Q4 25 | $126.0M | $12.3M | ||
| Q3 25 | $108.7M | $7.0M | ||
| Q2 25 | $79.3M | $9.1M | ||
| Q1 25 | $33.9M | $10.0M | ||
| Q4 24 | $75.0M | $16.4M | ||
| Q3 24 | $70.5M | $2.6M | ||
| Q2 24 | $42.0M | $10.1M | ||
| Q1 24 | $31.1M | $5.6M |
自由现金流率HRMYRGR
| Q4 25 | 51.7% | 8.2% | ||
| Q3 25 | 45.4% | 5.5% | ||
| Q2 25 | 39.6% | 6.9% | ||
| Q1 25 | 18.3% | 7.4% | ||
| Q4 24 | 37.3% | 11.2% | ||
| Q3 24 | 37.9% | 2.1% | ||
| Q2 24 | 24.3% | 7.7% | ||
| Q1 24 | 20.1% | 4.1% |
资本支出强度HRMYRGR
| Q4 25 | 0.0% | 2.1% | ||
| Q3 25 | 0.0% | 4.6% | ||
| Q2 25 | 0.0% | 4.2% | ||
| Q1 25 | 0.1% | 0.8% | ||
| Q4 24 | 0.3% | 2.5% | ||
| Q3 24 | 0.0% | 5.5% | ||
| Q2 24 | 0.4% | 6.6% | ||
| Q1 24 | 0.0% | 1.3% |
现金转化率HRMYRGR
| Q4 25 | 5.61× | — | ||
| Q3 25 | 2.14× | 8.15× | ||
| Q2 25 | 1.99× | — | ||
| Q1 25 | 0.75× | 1.43× | ||
| Q4 24 | 1.53× | — | ||
| Q3 24 | 1.53× | 1.98× | ||
| Q2 24 | 3.68× | 2.27× | ||
| Q1 24 | 0.81× | 1.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HRMY
暂无分部数据
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
